Front. Nutr. Frontiers in Nutrition Front. Nutr. 2296-861X Frontiers Media S.A. 10.3389/fnut.2025.1661669 Nutrition Correction Correction: Effect of Bifidobacterium longum subsp. infantis YLGB-1496 on common diseases in pediatrics: a randomized, blinded, placebo-controlled trial Zhang Xi 1 † Chen Ke 2 * † Lan Hanglian 3 † Chen Haixia 4 Chen Hua 4 Yang Ping 5 He Nianyang 5 Hung Weilian 3 Zeng Zaozhong 3 Liu Changqi 6 1Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China 2Department of Nutrition, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China 3National Center of Technology Innovation for Dairy, Hohhot, China 4Baoxing Center for Disease Control and Prevention, Yaan, China 5Department of Child Health Care, Xindu Maternal and Child Health Care Hospital, Chengdu, China 6School of Exercise and Nutritional Sciences, San Diego State University, San Diego, CA, United States

Edited and reviewed by: Michael J. Barratt, Washington University in St. Louis, United States

 *Correspondence: Ke Chen kechen@uestc.edu.cn

†These authors share first authorship

 04 08 2025 2025 12 1661669 08 07 2025 22 07 2025 Copyright © 2025 Zhang, Chen, Lan, Chen, Chen, Yang, He, Hung, Zeng and Liu. 2025 Zhang, Chen, Lan, Chen, Chen, Yang, He, Hung, Zeng and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on Effect of Bifidobacterium longum subsp. infantis YLGB-1496 on common diseases in pediatrics: a randomized, blinded, placebo-controlled trial by Zhang, X., Chen, K., Lan, H., Chen, H., Chen, H., Yang, P., He, N., Hung, W., Zeng, Z., and Liu, C. (2025). Front. Nutr. 12:1585504. doi: 10.3389/fnut.2025.1585504 probiotics short chain fatty acids children gut microbiota upper respiratory tract infection section-at-acceptance Nutrition and Microbes

In the published article, there was an error in Table 2, “Comparison of the days of common symptoms in infants and young children during the intervention period” as published.

The positions of “IG” and “CG” in the column headings were erroneously swapped. Similarly, “44 0.89” and “99 2.2” in the “Fever” row were incorrectly switched.

The corrected Table 2 appears below.

Comparison of the days of common symptoms in infants and young children during the intervention period.

Common symptoms CG (N = 50) IG (N = 50) p-value
Total occurrence days Incident rate per 100 intervention days (%)† Total occurrence days Incident rate per 100 intervention days (%)†
Cough* 190 4.22 99 2.2 < 0.001
Runny nose 171 3.8 136 3.02 0.133
Stuffy nose 120 2.67 83 1.84 0.066
Fever* 99 2.2 40 0.89 < 0.001
Loose stools 97 2.16 120 2.67 0.413
Increased frequency of bowel movements 105 2.33 105 2.33 0.921
Colic of the intestines 105 2.33 102 2.27 0.979
Dry stool* 346 7.69 157 3.49 0.012
Choking 45 1 58 1.29 0.387
Increased belching/bloating/anal gas 87 1.93 89 1.98 0.915
Retching/vomiting 35 0.78 52 1.16 0.244
Stool with milk flaps/food residues/sour odor 183 4.07 194 4.31 0.867
Reflux 58 1.29 64 1.42 0.393
Decreased appetite 181 4.02 135 3 0.285
Dysphoria 225 5 151 3.36 0.659
Refusal to eat 83 1.84 145 3.22 0.065
Eczematous changes of the skin* 578 12.84 134 2.98 0.002
Erythematous changes in the skin 12 0.27 9 0.2 0.958
Skin wheal-like changes 10 0.22 7 0.16 0.552

†A total of 9,000 study days (calculated method: 180 days × 50 people). Symptom incidence per 100 intervention days = duration of a symptom/total intervention days × 100%.

*Mann–Whitney U-test for two independent samples, p-values < 0.01. Dry stool refers to stool Bristol score type 1–3 stool.

IG, intervention group; CG, control group.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.